Patents by Inventor Daniel Lundell
Daniel Lundell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110213029Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.Type: ApplicationFiled: May 6, 2011Publication date: September 1, 2011Applicants: Schering Corporation, Pharmacopeia Drug DiscoveryInventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, JR., Laura L. Rokosz, Gaifa Lai, James P. Jakway, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
-
Patent number: 7960433Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).Type: GrantFiled: February 14, 2007Date of Patent: June 14, 2011Assignee: Schering CorporationInventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
-
Publication number: 20090306079Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.Type: ApplicationFiled: January 13, 2009Publication date: December 10, 2009Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, JR., Laura L. Rokosz, Gaifa Lai, James P. Jakway, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
-
Publication number: 20080090823Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.Type: ApplicationFiled: September 26, 2007Publication date: April 17, 2008Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
-
Patent number: 7358352Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: November 13, 2006Date of Patent: April 15, 2008Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Publication number: 20070248594Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.Type: ApplicationFiled: July 10, 2007Publication date: October 25, 2007Inventors: Jianhua Chao, Arthur Taveras, Cynthia Aki, Daniel Lundell, Jay Fine, Tony Priestley, Angelo Reggiani
-
Publication number: 20070155756Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).Type: ApplicationFiled: February 14, 2007Publication date: July 5, 2007Inventors: Arthur Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay Fine, Loretta Bober, Jianhua Chao, Purakkattle Biju, Younong Yu
-
Publication number: 20070141603Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: ApplicationFiled: November 13, 2006Publication date: June 21, 2007Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles Lunn, Jimmy Tan, Paul Zavodny
-
Publication number: 20070021494Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.Type: ApplicationFiled: August 8, 2006Publication date: January 25, 2007Inventors: Arthur Taveras, Cynthia Aki, Richard Bond, Jianping Chao, Michael Dwyer, Johan Ferreira, Jianhua Chao, Younong Yu, John Baldwin, Bernd Kaiser, Ge Li, J. Merritt, Purakkattle Biju, Kingsley Nelson, Laura Rokosz, Gaifa Lai, James Jakway, Minglang Wu, Evan Hecker, Daniel Lundell, Jay Fine
-
Patent number: 7135555Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: May 14, 2002Date of Patent: November 14, 2006Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 7132445Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.Type: GrantFiled: July 30, 2003Date of Patent: November 7, 2006Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Jr., Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
-
Publication number: 20060223864Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.Type: ApplicationFiled: December 16, 2004Publication date: October 5, 2006Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
-
Publication number: 20060025453Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.Type: ApplicationFiled: December 20, 2004Publication date: February 2, 2006Inventors: Arthur Taveras, J. Merritt, John Baldwin, Junying Zheng, Purakkattle Biju, Younong Yu, Jianhua Chao, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani, Gaifa Lai, Minglang Wu
-
Publication number: 20060014794Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.Type: ApplicationFiled: May 11, 2005Publication date: January 19, 2006Inventors: Jianhua Chao, Arthur Taveras, Cynthia Aki, Daniel Lundell, Jay Fine, Tony Priestley, Angelo Reggiani
-
Publication number: 20040147559Abstract: There are disclosed compounds of the formula 1Type: ApplicationFiled: July 30, 2003Publication date: July 29, 2004Applicant: Schering Corporation and Pharmacopeia, Inc.Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
-
Publication number: 20040053953Abstract: Methods of treating chemokine-mediated diseases are disclosed.Type: ApplicationFiled: March 17, 2003Publication date: March 18, 2004Applicant: Schering CorporationInventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
-
Patent number: 6531290Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: October 17, 2001Date of Patent: March 11, 2003Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Publication number: 20020168755Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: ApplicationFiled: May 14, 2002Publication date: November 14, 2002Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Publication number: 20020106781Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: ApplicationFiled: October 17, 2001Publication date: August 8, 2002Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 6319681Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: September 17, 1998Date of Patent: November 20, 2001Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny